Milone G A, Martínez Rolón J, Fernández I I, Corrado C S, Desmery P M, Dignani M C, Juni M, Pavlovsky S
FUNDALEU, Centro de Internación e Investigación Clínica Angélica Ocampo, Buenos Aires.
Medicina (B Aires). 2000;60(1):115-24.
Between August 1991 and December 1998, 400 patients (lymphomas: 197; acute leukemia: 86; multiple myeloma: 70 and solid tumors: 47) were admitted for autologous transplantation. All patients were mobilized with chemotherapy plus G-CSF. The hematological recovery was similar in all disease groups. Patients with acute leukemias and multiple myeloma had a slower platelet recovery. Treatment-related death was 4.5%. The status of the disease at diagnosis was the most significant prognostic factor. With a median follow-up of 23 months the probability of event-free survival at 60 months was 46% for low grade lymphoma, 44% for intermediate and high grade lymphoma, 58% for Hodgkin's disease, 45% for acute myeloblastic leukemia, 38% for solid tumors and 15% for multiple myeloma. The probability of survival at 60 months was 67% for low grade lymphoma, 47% for intermediate and high grade lymphoma, 75% for Hodgkin's disease, 52% for acute myeloblastic leukemia, 54% for solid tumors and 25% for multiple myeloma. It can be concluded that autologous progenitor cell transplantation induces a complete and faster hematological recovery in all groups of patients without any late graft failure. Results are similar to those published in the literature. The treatment-related death was low and acceptable.
1991年8月至1998年12月期间，400例患者（淋巴瘤：197例；急性白血病：86例；多发性骨髓瘤：70例；实体瘤：47例）接受了自体移植。所有患者均采用化疗加粒细胞集落刺激因子进行动员。所有疾病组的血液学恢复情况相似。急性白血病和多发性骨髓瘤患者的血小板恢复较慢。治疗相关死亡率为4.5%。诊断时的疾病状态是最重要的预后因素。中位随访23个月时，低级别淋巴瘤60个月无事件生存率为46%，中高级别淋巴瘤为44%，霍奇金病为58%，急性髓细胞白血病为45%，实体瘤为38%，多发性骨髓瘤为15%。60个月时的生存率，低级别淋巴瘤为67%，中高级别淋巴瘤为47%，霍奇金病为75%，急性髓细胞白血病为52%，实体瘤为54%，多发性骨髓瘤为25%。可以得出结论，自体祖细胞移植可使所有患者组实现完全且更快的血液学恢复，且无任何晚期移植物失败。结果与文献报道相似。治疗相关死亡率较低且可接受。
